Lung Cancer
-
Exkivity (Mobocertinib) – NSCLC | HongKong DengYue Medicine
-
Purocenta (Para‑toluenesulfonamide) – NSCLC | DengYueMed
-
Cejemly (Sugemalimab) – NSCLC | DengYue Medicine
-
Arelili (Adebrelimab) – ES-SCLC | HongKong DengYue Medicine
-
Cosela (Trilaciclib) – ES-SCLC | HongKong DengYue Medicine
-
Tecentriq (Atezolizumab) – ES-SCLC | DengYue Medicine
-
Qixinke (Iruplinalkib) | NSCLC | HongKong DengYue Medicine
-
Alunbrig (Brigatinib) | NSCLC | HongKong DengYue Medicine
-
Gavreto (Pralsetinib) – NSCLC | HongKong DengYue Medicine
-
Ivesa (Furmonertinib Mesylate) – NSCLC | DengYueMed
-
Ensacove (Ensartinib Hydrochloride) – NSCLC | DengYueMed
-
Ameile (Aumolertinib Mesylate) – NSCLC | DengYueMed
-
Tevimbra (Tislelizumab-jsgr) – NSCLC | DengYueMed
-
Mekinist (Trametinib) – NSCLC | DengYue Medicine
-
Tafinlar (Dabrafenib) – NSCLC | DengYue Medicine
-
Imfinzi (Durvalumab) – NSCLC | DengYue Medicine
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights